関連する実験動画
Updated: Aug 6, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
ティクロピジンとクロピドグレルグリル
1Department of Clinical Pharmacology, The Royal College of Surgeons in Ireland, Dublin, Ireland.
Circulation
|October 12, 1999
まとめ
チクロピジンやクロピドグレルのようなチエノピリジンは,ADP受容体を阻害することによって,血小板の集積を阻害する. ティクロピディンは,心血管疾患の予防に有効ですが,深刻な副作用があり,クロピドグレロゲルです.
科学分野:
- 薬理学 薬理学とは
- 心血管医学 心血管医学
- 血液学 ヘマトロジ
背景:
- ティエノピリジンは,ティクロピジンとクロピドグレルを含む,血小板凝集の確立された阻害剤です.
- そのメカニズムは,血小板のADP受容体に対抗する活性代謝物への変換を伴う.
- 血小板抑制の発症は遅れており,最大効果は数日後,回復が遅くなる.
研究 の 目的:
- ティクロピジンとクロピドグレルの有効性および安全性プロフィールをレビューする.
- 心血管疾患の予防におけるアスピリンとの効果を比較する.
- クロピドグレルの役割,特にアスピリンと併用する際の未解決の問題を特定する.
主な方法:
- ティエノピリジン抗血小板剤に関する研究の文献レビュー.
- ティクロピジンとクロピドグレルをアスピリンと比較した臨床試験データの分析.
- 報告された有害事象と治療結果の評価.
主要な成果:
- ティクロピジンは血管疾患においてアスピリンに匹敵する有効性を示しているが,中性不全のような重度の副作用のリスクが伴う.
- クロピドグレルはアスピリンと同じくらい効果があり,ティクロピジンよりも安全であるようです.
- 急性冠動脈症候群およびステント置換後のクロピドグレルの有効性に関するデータは限られている.
結論:
- クロピドグレルは,心血管疾患の予防のためにチクロピジンに比べて,潜在的に安全な代替品です.
- クロピドグレルとアスピリンの併用による追加的利益と安全性を決定するために,さらなる研究が必要である.
- クロピドグレルとアスピリンの組み合わせは,抗血栓性療法における将来の標準を代表する可能性があります.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

